NDA Submitted for Olinvo to Treat Moderate to Severe Acute Pain

Share this content:
Olinvo provided rapid and powerful analgesic efficacy while demonstrating a wider therapeutic window compared to morphine
Olinvo provided rapid and powerful analgesic efficacy while demonstrating a wider therapeutic window compared to morphine

Trevena has submitted their New Drug Application (NDA) to the Food and Drug Administration for Olinvo (oliceridine injection) for the management of moderate-to-severe pain in the hospital and similar settings.

Olinvo is a next generation IV analgesic and the first G protein biased ligand of the mu receptor, a new class of opioid receptor modulator. The NDA includes data from two Phase 3 APOLLO pivotal studies and also the ATHENA study. In total 1,100 patients were administered Olinvo during the studies. The APOLLO-1 and APOLLO-2 trials evaluated the efficacy of oliceridine for 48 hours following bunionectomy and 24 hours following abdominoplasty, respectively. 

Patients received a loading dose of placebo, morphine 4mg or oliceridine 1.5mg, followed by on-demand doses of the same study drug (morphine 1mg or oliceridine 0.1mg, 0.35mg, or 0.5mg) via patient controlled analgesia. Results from APOLLO-1 showed that all three doses of oliceridine (0.1mg, 0.35mg, 0.5mg) demonstrated statistically greater analgesic efficacy than placebo at 48 hours post-bunionectomy (P<0.0001). Additionally, findings from the APOLLO-2 study showed that all 3 oliceridine doses demonstrated statistically superior responder rates vs. placebo at 24 hours post-abdominoplasty.

In the ATHENA study, 772 patients were administered Olinvo to manage pain associated with a wide range of procedures and diagnoses. The most frequent procedures were orthopedic, gynecologic, colorectal, general, and plastic surgeries. 

"Despite availability of non-opioid analgesics and advances in multimodal analgesia, tens of millions of patients still require IV opioids following surgery, during severe illness, or after trauma," said Maxine Gowan, PhD, CEO. "We look forward to working with the FDA during the review process and to a potential NDA approval of Olinvo in 2018."

In a statement, the Company said they expect Olinvo to be a Schedule II controlled substance. 

For more information visit Trevena.com.

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters